Cardiff Oncology, Inc.
CRDF
NASDAQ·Healthcare·Biotechnology·Mkt cap $84.0M
$1.09
▲ +0.93%
P/E
-1.82
Mkt Cap
$84.0M
52-Wk Range
$0.76–$3.31
52-Week Range
$0.76 - $3.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 51.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective PLK1 inhibition mechanism with differentiated pharmacology
- Diversified clinical pipeline targeting multiple cancer indications and patient populations
- Combination therapy approach enhancing efficacy in difficult-to-treat cancers
- Oral drug formulations improving patient convenience and compliance
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-27.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRDF right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 11, 2026
Reported EPS of -$0.14 vs -$0.12 consensus (-17.0% surprise). Revenue of $104.0K vs $62.8K expected (+65.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-17.0%
Revenue trend · last 8Q
—
-3%
-47%
-26%
-27%
+61%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$165.0K
$151.0K
$109.0K
$121.0K
$120.0K
$243.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
4 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: William Blair · Aug 11, 2026
vs Industry
How CRDF stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related